A phase I clinical trial is currently studying the safety and toxicity of a vaccine to prevent recurrence of cancer in patients with non-metastatic, node positive, HER2 negative breast cancer who are in remission [115], and vaccine strategies are being tested in patients with HER2+ ductal carcinoma in situ (DCIS) [116]. The gene discussed is ERBB2; the disease is breast carcinoma.